SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-23-013902
Filing Date
2023-10-03
Accepted
2023-10-03 17:00:54
Documents
1
Period of Report
2023-09-29

Document Format Files

Seq Description Document Type Size
1 form4-10032023_051032.html 4  
1 form4-10032023_051032.xml 4 4572
  Complete submission text file 0001415889-23-013902.txt   6183
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TOBIRA THERAPEUTICS, INC. 701 GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address
Melincoff Gwen A (Reporting) CIK: 0001614890 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 231305058